The purpose of this study was to ascertain the risk of non-melanocytic skin cancer (NMSC) in simultaneous pancreas kidney transplant recipients (SPKTRs) compared to kidney transplant recipients (KTRs) in relation to other potential risk factors of skin cancer. In a cohort study, 208 SPKTRs were compared with 1,111 KTRs who were transplanted during the same time period. The effects of age, sex, country of origin, time period after transplantation, HLA matching, immunosuppressive regimen and rejection treatments on the risk of NMSC were investigated in multivariable Cox's proportional hazard models. In SPKTRs the incidence of NMSC increased from 19 to 36%, respectively 10 and 15 years after transplantation which was significantly higher compared with that in KTRs (6 and 10%, respectively). After adjustment for age and sex, SPKTRs had a 6.2 (3.0-12.8) increased risk of squamous-cell carcinoma (SCC) compared to KTRs. An additional adjustment for maintenance immunosuppression decreased the hazard ratio to 3.1 (1.3-7.2) which indicates partial confounding by the immunosuppressive regimen. Adjustment for induction and rejection therapy or HLA mismatching did not change the hazard ratio significantly. SPKTRs have an increased risk of SCC compared with KTRs, despite partial confounding by the immunosuppressive regimen.
Introduction
Organ-transplant recipients are at increased risk for post-transplant neoplasms (Hardie et al, 1980; Hartevelt et al, 1990) . Non-melanocytic skin cancers (NMSCs), especially squamous-cell carcinomas (SCC), are the most common malignancies and can cause substantial morbidity and even mortality (Hartevelt et al, 1990; Bouwes Bavinck et al, 1996; Naldi et al, 2000; Jensen et al, 2000; Euvrard et al, 2003; Otley et al, 2005b; Moloney et al, 2006) .
Increasing age, male sex, and fair complexion are the most important host-related risk factors for skin cancer, and exposure to sunlight, smoking and infection with human papillomaviruses are the most important environmental risk factors (De Hertog et al, 2001; Kasiske et al, 2004; Bouwes Bavinck and Feltkamp, 2004; Bouwes Bavinck et al, 2008) . Among organ-transplant recipients, immunosuppressive therapy forms an additional important risk factor (Hartevelt et al, 1990; Bouwes Bavinck et al, 2007) . Both the duration and type of immunosuppression may play a role. Azathioprine (Aza) has been reported to induce selective UVA photosensitivity, which may result in a cascade of reactions in the skin, ranging from the induction of oxidative stress and mutagenic DNA lesions to the development of skin cancer (O'Donovan et al, 2005; Ulrich and Stockfleth, 2007; Cooke et al, 2007; Montaner et al, 2007) . Cyclosporine A (CsA) can decrease DNA repair and impair UV-induced apoptosis, which also increases the risk of skin cancer (Yarosh et al, 2005) . Poor HLA matching has been reported to be associated with an increased risk of NMSC (Bouwes Bavinck et al, 1991) .
Among kidney-transplant recipients (KTRs) living in a temperate climate, the prevalence of NMSC at 10 years after transplantation varied between 10 and 27% and at 20 years between 40 and 60% (Hartevelt et al, 1990; Bordea et al, 2004; Moloney et al, 2006) . In Australia, the incidence is even higher (Hardie et al, 1980; Bouwes Bavinck et al, 1996; Ramsay et al, 2002) . Heart-transplant recipients seem to have a higher incidence of NMSC compared with KTRs, although this may be a consequence of older age at transplantation in this group (Mihalov et al, 1996; Naldi et al, 2000; Fortina et al, 2000) . Less research has been conducted in patients receiving a liver transplant.
After a follow-up period of 10 years, an incidence between 13 and 26% has been found in Dutch and Spanish liver-transplant recipients, respectively (Haagsma et al, 2001; Herrero et al, 2005) . There are no studies that followed up lung-transplant recipients or simultaneous pancreas kidney transplant recipients (SPKTRs) for a longer period.
Since 1986, simultaneous pancreas kidney transplantations (SPKTs) are being performed in the Netherlands. At present, more than 200 patients received an SPKT at risk of skin cancer in spk tr and k tr the Leiden University Medical Center (LUMC). The main objective of this study was to calculate the cumulative incidence of skin cancer in SPKTRs compared with the incidence in KTRs who were transplanted in the same center during the same time period.
We hypothesized that the risk of skin cancer in SPKTRs would be higher compared with that in KTRs, because SPKTRs are exposed to a more potent immunosuppressive regimen and are not HLA-matched in contrast to KTRs.
Results

Baseline characteristics of the KTR and SPKTR
The baseline characteristics of the KTRs and SPKTRs are depicted in Table 1 . The majority of the patients originated from the Netherlands. In the KTR group, there were significantly more patients originating from Mediterranean countries or from countries that are associated with a darker skin type (Table 1) . Sex distribution did not differ significantly between the two groups, but the SPKTRs were on an average 7.4 years younger at first transplantation than were the KTRs (P < 0.001). The median follow-up time of the SPKTRs was shorter (P = 0.014), because, during the first few years, the number of SPKTs was still limited (Table 1) . After adjustment for age, sex and immunosuppressive therapy, overall survival was significantly shorter for SKPTRs compared with KTRs, with an adjusted hazard ratio of 2.1 (1.5-3.1).
Cumulative incidence of skin cancer in the SPKTR compared with that in the KTR
The baseline characteristics of the KTRs and SPKTRs in relation to the development of SCC and basal-cell carcinoma (BCC) as first events are depicted in Table 2 , and potential risk factors for NMSC, SCC and BCC are presented for KTRs and SPKTRs, separately, in Supplementary Figure S1 and Supplementary Tables S1a and S1b. Two of the KTRs had developed an SCC and a BCC and four only a BCC before transplantation. These skin cancers were not considered in the analyses. None of the SPKTRs had developed an SCC or a BCC before transplantation. The time period after transplantation was significantly associated with the occurrence of SCC and BCC (P < 0.001), but sex was not associated with skin cancer (Table 2 ). In the Cox's proportional hazard model, increasing age at transplantation was a risk factor for both types of skin cancer (Supplementary Tables S1a and S1b) .
During the follow-up period until June 2007, a total of 109 skin cancers (73 SCCs and 36 BCCs) were diagnosed in 26 (12.5%) out of 208 SPKTRs (Table 2) . During the chapter 5 same follow-up period, 68 (6.1%) out of 1,111 KTRs developed altogether 223 skin cancers (102 SCCs and 121 BCCs). The overall SCC:BCC ratio in the KTR was 0.79. This ratio gradually increased with increasing time after transplantation with ratios of 0.67, 0.55, 0.71, and 1.0 during the first 2, 2-7, 8-12, and 13-17 years after transplantation, respectively. The overall SCC:BCC ratio in the SPKTR was 1.1. The ratios were 0, 1.1, and 1.4 during the periods between 2-7, 8-12, and 13-17 years after transplantation, respectively.
The cumulative incidences of NMSC, SCC and BCC in SPKTRs are compared with those in KTRs in Figure 1 and Supplementary Figure S2 .
risk of skin cancer in spk tr and k tr 5 *KTR = kidney transplant recipient, SPKTR = simultaneous pancreas kidney transplant recipient. ** After adjustment for age, sex and immunosuppressive therapy overall survival was significantly shorter for SKPTR compared to KTR with an adjusted hazard ratio of 2.1 (1.5;3.1). Figure S1 and Supplementary Tables S1a and S1b).
HLA matching and skin cancer
No HLA matching is carried out in SPKTRs. Therefore, the number of mismatches was much higher among the SPKTRs than in KTRs (Table 1) . HLA mismatching, however, chapter 5 Figure 1 Cumulative incidence of skin cancer in 208 simultaneous pancreas kidney transplant recipients (SPKTR) compared to 1111 kidney transplant recipients (KTR). The numbers of SPKTR and KTR at risk in relation to the years after transplantation are indicated in the Table. was not significantly associated with SCC or BCC in either the KTRs or the SPKTRs (Table 2 , Supplementary Figure S1f and Supplementary Tables S1a and S1b).
Immunosuppressive regimens and skin cancer
The immunosuppressive regimens differed strongly between SPKTRs and KTRs, and changed considerably during the years (Table 3 ). SPKTRs always received triple therapy, whereas this regimen was introduced much later in KTRs (Table 3 ).
In both KTRs and SPKTRs, immunosuppressive regimens were associated with the development of SCC but not of BCC ( Table S1a ).
In the SPKTR group, immunosuppression with MMF compared with that with Aza was also associated with a decreased risk of SCC (Supplementary Figure S1e , SCC). The hazard ratio could not be calculated, however, because all SCC cases were immunosuppressed with Aza in any combination and none with MMF in any combination ( Tables S1a and S1b ).
In the SPKTR, we also calculated the median daily Table 4 . Age, sex and maintenance immunosuppression*** 3.0 (1.7;5.5) 3.1 (1.3;7.2) 3.1 (1.4;6.9)
Age, sex and ATG or OKT3 as induction or rejection treatment 3.9 (2.3;6.7) 6.3 (2.9;13.9) 2.9 (1.4;6.2)
Age, sex and level of immunosuppression**** 2.4 (1.0;5.9) 6.5 (1.7;25. Figure S2 ). Supplementary Figure   S2d shows that SPKTRs were much younger at transplantation than were KTRs.
Adjustment for age, therefore, increased the hazard ratio for the association between transplanted organ and SCC (Table 4 ). Supplementary Figure S2f shows that risk of SCC was much lower in the group of patients who were immunosuppressed with MMF in any combination. Adjustment for maintenance immunosuppression decreased the hazard ratio for the association between transplanted organ and SCC, which was adjusted for age and sex from 6.2 (3.0-12.8) to 3.1 (1.3-7.2), which suggests a partial confounding by maintenance immunosuppression (Table 4) . Adjustment for other potentially confounding factors did not reduce the hazard ratios for SCC notably (Table 4 ).
The risk of BCC in SPKTR compared with that in KTR was reduced after adjustment for HLA mismatching and for the level of immunosuppression, and, when all relevant potentially confounding factors were introduced into the Cox's proportional hazard model, the increased risk of BCC largely disappeared (Table 4) .
Discussion
This study showed, after adjustment for age and sex, a 6.2-fold (95% CI: 3.0-12.8)
increased risk of SCC in SPKTRs than in KTRs who were transplanted in the same center during the same time period. After an additional adjustment for maintenance immunosuppression, this risk decreased to 3.1 (1.3-7.2). The risk of BCC was not statistically significantly increased in SPKTRs after adjustment for potentially confounding factors.
Maintenance immunosuppressive therapy with MMF in any combination had led to a significantly decreased risk of SCC compared with maintenance immunosuppressive therapy with Aza. SPKTRs were more often immunosuppressed with Aza than were KTRs. Adjustment for this factor, indeed, reduced the risk of SCC in SPKTRs compared with that in KTRs, suggesting that the increased risk of SCC in SPKTR can be partly explained by confounding by the type of maintenance immunosuppressive therapy. There remained, however, a statistically significant three-fold increased risk of SCC in SPKTR, for which we looked for other potential explanations.
Apart from an obligate history of diabetes in the SPKTRs and differences in maintenance immunosuppression, other differences discerning SPKTRs from KTRs are more frequent induction and rejection therapies, and the absence of HLA matching risk of skin cancer in spk tr and k tr 98 in SPKTRs. Moreover, these factors could potentially explain the increased risk of SCC in SPKTRs compared with that in KTRs.
The incidence of NMSC in patients with type 1 diabetes has not been systematically studied (Zendehdel et al, 2003; Swerdlow et al, 2005) . Only Zendehdel et al (2003) showed a modest, but statistically nonsignificant increase of NMSC, with a standardized incidence ratio of 1.9 (0.6-4.3) in patients who had type 1 diabetes mellitus for more than 15 years (Zendehdel et al, 2003) . In organ-transplant recipients, diabetes was associated with a decreased risk of NMSC (Kasiske et al, 2004; Otley et al, 2005a) . It is therefore not likely that type 1 diabetes may explain the increased risk of SCC among SPKTRs.
Induction treatments, impending graft rejection, and the subsequent rejection therapies were not associated with SCC or BCC in this study, although the follow-up periods may still have been too short to detect such an effect. Adjustment for induction and rejection treatments did not change the increased risk of SCC in SPKTRs, excluding also these factors as major causes for the increased risk of SCC in SPKTRs.
Although HLA matching has been reported to be associated with skin cancer in an earlier study (Bouwes Bavinck et al, 1991) , we were not able to confirm this association in this study. Adjustment for HLA matching did not influence the risk of SCC among SPKTRs; hence, poor HLA matching could not explain the increased risk of SCC in SPKTRs. The risk of BCC in SPKTRs, compared with that in KTRs, however, decreased after adjustment for HLA matching, suggesting that poor HLA matching could partly explain the increased risk of BCC in SPKTRs.
Differences in the number of induction and graft rejection treatments, as well as HLA matching, did not provide a good explanation for the increased risk of SCC in SPKTRs compared with KTRs. However, other differences between the two groups might be responsible for this outcome. Compared with KTRs, in SPKTRs, a second transplanted organ is present. Induction of tolerance is an important goal of clinical organ transplantation (Kean et al, 2006; Kawai et al, 2008) , and may also have undesirable side effects, such as an increased risk of skin cancer. We speculate that transplanted pancreas may induce tolerance against an additional set of allo-peptides in the HLA antigens of the donor. Although we are not aware of any published examples of this mechanism in humans who have received a double set of other organs (for example, heart and lung), a reduced rejection rate of the transplanted heart has been described in rats who received a heart in combination with a lung or spleen (Westra et al, 1991 ). An increased cross-reactive tolerance against SCC-associated antigens in the host could then lead to an increased risk of SCC in SPKTRs, which could potentially affect SCC more severely than BCC, as SCCs are more antigenic cancers than are BCCs (Muchemwa et al, 2006) . Future studies should point out whether this hypothesis is true.
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The overall SCC:BCC ratio in this study was 0.79, which is lower than the ratio of 1.6 in our earlier study (Hartevelt et al, 1990) . After the introduction of maintenance therapy with MMF instead of Aza, a decreased risk of SCC was observed, while the risk of BCC was not decreased or even possibly increased. Therefore, this change in maintenance therapy may explain, at least partly, the lower SCC:BCC ratio. The length of the follow-up period may form another explanation, as BCCs tend to occur earlier after transplantation than SCCs, but after a latent period, the cumulative incidence of SCC increases more rapidly than that of BCC.
The high collinearity of the immunosuppressive regimen, as well as HLA matching with the type of organ transplanted and the relatively limited numbers of first events, is the most important limitation of this study. The high collinearity could easily result in overfitting in the model so that the association between transplanted organ and skin cancer could disappear. The limited numbers of first events provided insufficient power, limiting the number of reliable stratified analyses.
As the risk of developing skin cancers in transplant recipients is highly increased, excessive exposure to sunlight should be avoided and use of daily sunscreen should be advised. In addition, strict control in an outpatient clinic is important for diagnosing skin cancers at an early stage, facilitating the best treatment and preventing further complications. 
Materials and methods
Patients
Collection of data
Data recorded for all SPKTRs and KTRs included the country of origin, the dates of the transplantations, age at transplantation, sex, and the dates of death or last follow-up visit.
During the first post-transplant years, all patients with functional grafts were seen in the Department of Nephrology, LUMC. Only 88 (6.7%) patients (4 SPKTRs and 84 KTRs) were later followed up in other centers in the Netherlands. In total, 11 (0.8%) patients (1 SPKTR and 10 KTRs) were lost to follow-up, mainly because they moved to another country. Patients with skin problems were also seen and followed up at the Department of Dermatology, LUMC. Skin biopsies were routinely carried out when skin cancers were suspected. Skin cancer data were collected from the computerized oncological registry of the LUMC, the database from the department of Pathology, and from the national histological database (PALGRA). Follow-up data were collected until June
2007.
Of 1,111 KTRs, 9 recipients (5 with malignant melanoma, 2 with Kaposi's sarcoma, 1 with sweat gland carcinoma and 1 with fibrosarcoma) were present, but no SPKTR who developed skin cancers other than NMSC after transplantation. These skin cancers are not further discussed.
Immunosuppressive regimens and HLA matching
Information about the initial and maintenance immunosuppressive therapy of all patients was obtained from the Eurotransplant database. Type of induction therapy and the number and type of rejection treatments were collected from the flow sheets in the medical charts of the department of nephrology.
For SPKTRs, the initial and maintenance immunosuppressive therapy between 1986 and 1995 consisted of prednisolone (P) (7.5-10 mg/day), Aza (50-100 mg/day) and CsA (200-300mg/day). Between 1996 and 2001, almost all new patients were treated with prednisolone (7.5-10 mg/day), MMF (2,000 mg/day) and CsA (200-300 mg/day).
Since 2002 the immunosuppressive treatment of all new patients consisted of prednisolone (7.5-10 mg/day), MMF (1,000-1,500 mg/day) and Tac (6-10 mg/day).
In most SPKTRs, maintenance therapy was identical to initial treatment. Table 3 .
A total of 112 of the 208 SPKTRs received induction therapy to prevent a rejection of the graft by administration of OKT3 (24 patients SPKTRs and KTRs, in whom acute graft rejections were observed, were almost always initially treated with methylprednisolone. When this therapy was not sufficient to prevent further rejection, a second and third rejection treatment with ATG and once more with methylprednisolone, respectively, was given. In exceptional cases, OKT3 was given when a fourth rejection treatment was needed.
To estimate the level of immunosuppression, we categorized the patients into The degree of HLA mismatching for HLA-A, HLA-B, and HLA-DR antigens was assessed by counting the antigens present in the donor but absent in the recipient. The initial and maintenance immunosuppressive therapies were categorized into three basic treatment groups: duo or triple therapy with Aza in any combination, duo or triple therapy with MMF in any combination, and duo therapy without Aza or MMF (i.e. a combination of prednisolone with CsA or prednisolone with Tac). If no data were available for the maintenance immunosuppressive therapy, the data of the initial immunosuppressive therapy were used. For all our analyses with immunosuppressive therapy, we used the subcategorization of maintenance therapy because the patients were, generally, exposed to this regimen for the most prolonged period of time.
Statistical analyses
Because ATG and OKT3 exert by far the highest immunosuppressive effect, induction and rejection treatments were dichotomized into those with and without ATG and/or OKT3. Because the biological effects of ATG and OKT3 are supposed to be similar before and after the transplantation, exposures to ATG and/or OKT3 as induction or rejection treatment were also combined for our analyses.
Differences between patients with and without skin cancer were analyzed by
Chi-square (categorical variables) and Student's T-tests (continuous variables).
Kaplan-Meier survival analyses were used to estimate the cumulative incidence of skin cancer after transplantation. Cox's proportional hazard analyses were used to calculate hazard ratios for the development of skin cancer and to adjust for potentially confounding factors. As opening dates for both analyses, we used the date of the first transplantation; as closing dates, we used the date of diagnosis of the first SCC or BCC, the date of the patient's death, the date of last follow-up, the date that they were lost to follow-up, or, if the patients were still seen in an outpatient clinic, we used the date (Supplementary Figure S2) and in multivariable Cox's proportional hazard models (Table 4 ). The Cox's proportional hazard analyses were initially carried out without any adjustment and subsequently with adjustments for age and sex. The hazard ratios adjusted for age and sex were further adjusted for other potentially confounding factors (Table 4) . Age and sex, HLA matching and maintenance immunosuppression had the most important modulating effect on the association between transplanted organ and skin cancer, and these factors were, therefore, included in the final model. For the Mediterranean and Asia, Suriname or Africa group no Kaplan-Meier curve could be calculated. For the Mediterranean and Asia, Suriname or Africa group no Kaplan-Meier curve could be calculated. *Level of immunosuppression is calculated as follows: low; none of the three types of immunosuppression (triple, induction or rejection therapy) has been given, moderate; one of three types of immunosuppression (triple, induction or rejection) has been given, high; two of three types of immunosuppression (triple, induction or rejection) has been given, very high; all types of immunosuppression (triple, induction or rejection) has been given.
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ff Table S1a Risk factors of skin cancer in kidney transplant recipients adjusted for age and sex using Cox proportional hazard analysis. 
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Table S1b
Risk factors of skin cancer in simultaneous pancreas kidney transplant recipients adjusted for age and sex using Cox proportional hazard analysis. 
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